Gyre Therapeutics Reports Q3 Revenue of $32.9 Million and GAAP EPS of -$0.04
Gyre Therapeutics (NASDAQ: GYRE) has released its third-quarter financial results, reporting a GAAP earnings per share (EPS) loss of $0.04. The company's revenue for the quarter reached $32.9 million, representing a marginal year-over-year increase of 0.6%. Despite the slight quarterly revenue growth and ongoing net losses, management has affirmed its full-year 2026 revenue guidance, projecting between $100.5 million and $111 million. The results reflect the company's current stage of commercial scaling and financial positioning.
Topics: earnings GAAP EPS revenue guidance
Read the full article at Seeking Alpha
Part of the story Gyre Therapeutics Reports Q3 Revenue of $32.9 Million and GAAP EPS of -$0.04 (3 articles)